SCHEMBL12469226

SCHEMBL12469226

c1ccc(-n2nnnc2SCCCN2CCN(c3cccc4ccccc34)CC2)cc1

nearest known ligand 0.52

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 9/20 0.48
MEN1 O00255 2/20 0.48
KMT2A Q03164 2/20 0.48
HTT P42858 1/20 0.48
LMNA P02545 3/20 0.47
HPGD P15428 2/20 0.47
TSHR P16473 2/20 0.47
POLB P06746 1/20 0.47
NPSR1 Q6W5P4 1/20 0.47
MAPT P10636 2/20 0.46
L3MBTL1 Q9Y468 1/20 0.46
HTR1A P08908 2/20 0.45
TDP1 Q9NUW8 1/20 0.45
DRD2 P14416 1/20 0.45
HTR2A P28223 1/20 0.45
HTR2C P28335 1/20 0.45
DRD3 P35462 1/20 0.45
ADRB2 P07550 1/20 0.45
HTR3A P46098 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12469049 0.94 ALDH1A1 (0.48) ALDH1A1MEN1KMT2AHTTLMNA
SCHEMBL12469501 0.85 DRD2 (0.58) ALDH1A1LMNAHPGDTSHRPOLB
SCHEMBL12469002 0.80 ALDH1A1 (0.58) ALDH1A1HTTLMNAHPGDTSHR
SCHEMBL12469487 0.78 SLC6A2 (0.52) ALDH1A1LMNATSHRMAPTL3MBTL1
SCHEMBL12469317 0.78 NPSR1 (0.61) ALDH1A1TSHRNPSR1MAPTL3MBTL1
SCHEMBL12469349 0.78 SLC6A2 (0.56) ALDH1A1MEN1KMT2ALMNAHPGD
SCHEMBL15348353 0.76 HTR7 (0.48) HPGDHTR1ADRD2HTR2A
SCHEMBL12468950 0.75 ALDH1A1 (0.44) ALDH1A1LMNAHPGDTSHRPOLB
SCHEMBL12469254 0.74 ALDH1A1 (0.43) ALDH1A1LMNAHPGDTSHRPOLB
SCHEMBL10970208 0.74 ALDH1A1 (0.71) ALDH1A1MEN1KMT2ALMNAHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130289047-A1 HETEROARYLTHIO DERIVATIVES AND ANALOGUES EPIOMED THERAPEUTICS, INC. (US) 2013-10-31 US disclosed
WO-2012051601-A2 HETEROARYLTHIO COMPOUNDS EPIOMED THERAPEUTICS, INC. (US) 2012-04-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130289047-A1 HETEROARYLTHIO DERIVATIVES AND ANALOGUES NLN, HTT, ABAT ALDH1A1 2297/4885MEN1 2746/4885KMT2A 481/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.